Regulatory Approval

A new six-month injection for Central Precocious Puberty shows strong safety and efficacy, promising to ease the treatment burden for children and families.

Vertical Aerospace and Marubeni target 2026 demo flights in Osaka, accelerating Japan's race to launch commercial electric air taxi services.

As the FDA embraces advanced Bayesian statistics, MedTech firm BioStem sees validation for its wound care research, promising faster innovation for patients.

Commonwealth LNG's 20-year deal with Mercuria for 1 Mtpa of LNG nears project financing, despite facing significant environmental and regulatory hurdles.

The tire giant's latest deal for a sealing specialist signals an aggressive push into high-value materials, moving far beyond its rubber-and-road legacy.

The EpiFaith® Smart Syringe secures landmark deals with the UK's NHS and Paris's AP-HP, signaling a new era for patient safety and market access.

After a four-year campaign, the World Health Organization is poised to recognize a silent liver epidemic, setting the stage for a new global NCD strategy.

Canada's first compliant stablecoin, QCAD, partners with VersaBank, leveraging bank-grade security to bridge the gap between crypto and traditional finance.

A new partnership between tech firm OnBoard and Stanford experts aims to redefine corporate governance with AI, promising greater insight and accountability.

UK insurers face a tight deadline for tough new PRA collateral rules. A new solution from Transcend aims to ease the burden and enhance risk oversight.

Asurity and MISMO are spearheading a data revolution to standardize mortgage compliance, promising huge efficiency gains and a new era of regulatory clarity.

A major multi-vendor study confirms AI's power for precision HER2 scoring, promising to improve diagnostics and accelerate personalized cancer therapies.

Regulators deem PRRS-resistant pigs safe, promising a future with less animal disease and antibiotic use, but sparking debate on consumer transparency.

Quanterix has submitted a multi-biomarker blood test to the FDA, a move that could revolutionize early Alzheimer's diagnosis and patient care.

A bipartisan bill in Congress aims to give veterans access to emerging mental health treatments, including the novel, non-hallucinogenic compound MEAI.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

New Medicare rules expand access to opioid alternatives, reshaping post-surgery recovery and rewarding companies at the forefront of pain management.

A breakthrough in cancer therapy as Avacta's faridoxorubicin proves so safe, regulators have removed historic dosing limits tied to heart toxicity.

Relay Therapeutics' experimental drug, zovegalisib, offers new hope for a common and hard-to-treat form of advanced breast cancer with a promising safety profile.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.